Huawei launches new tablet in flagship phone hiatus
Huawei launches new tablet in flagship phone hiatus
The laptop, the Matebook X Pro, and the tablet, the MediaPad M5, were presented on the eve of the opening of the Mobile World Congress in Barcelona — the scene of previous major Huawei launches.
But this year the company will instead present its new flagship smartphone — the P20 — on March 27 in Paris, in what is seen as a bid not to be eclipsed by Samsung’s launch of its new top end phone later Sunday.
“By launching the new P20 smartphones only a month later in Paris, Huawei will be able to fine tune its marketing message based on how the new Samsung S9 devices are perceived by consumers,” said Forrester analyst Thomas Husson.
Both the new Huawei laptop and tablet feature long lasting batteries and quicker charge times and are available in grey and silver.
The laptop’s power button doubles as a fingerprint scanner, which Huawei says will start and securely log into Windows in under eight seconds.
Huawei also unveiled what it said is the world’s first commercial chipset that meets the standards of the super-fast 5G wireless networks which are poised to start being rolled out.
The company said the chipset can hit download speeds of 2.3 gigabits per second, significantly faster than speeds reached in current 4G networks.
Huawei remained the world’s third biggest seller of smartphones in 2017, behind Samsung and Apple.
It boasted a 10.4 percent market share, up from 9.5 percent, according to research firm IDC.
Samsung had a 21.6 percent share while Apple held 14.7 percent.
Fall of top US scientists points to ethics gap in research
- Links between a doctor leading a clinical trial and manufacturers of drugs or medical equipment used in the study can influence the methodology and ultimately the results
WASHINGTON: Three prominent US scientists have been pushed to resign over the past 10 days after damning revelations about their methods, a sign of greater vigilance and decreasing tolerance for misconduct within the research community.
The most spectacular fall concerned Jose Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center in New York. He authored hundreds of articles on cancer research.
Investigative journalism group ProPublica and The New York Times revealed on September 8 that Baselga failed to disclose in dozens of research articles that he had received millions of dollars from pharmaceutical and medical companies.
Such declarations are generally required by scientific journals.
Links between a doctor leading a clinical trial and manufacturers of drugs or medical equipment used in the study can influence the methodology and ultimately the results.
But journals don’t themselves verify the thoroughness of an author’s declarations.
Caught up in the scandal, Baselga resigned on September 13.
Next came the case of Brian Wansink, director of the Food and Brand Lab at the prestigious Cornell University.
He made his name thanks to studies that garnered plenty of media attention, including on pizza, and the appetites of children.
His troubles began last year when scientific sleuths discovered anomalies and surprisingly positive results in dozens of his articles.
In February, BuzzFeed published messages in which Wansink encouraged a researcher to extract from her data results more likely to go “viral.”
After a yearlong inquiry, Cornell announced on Thursday that Wansink committed “academic misconduct in his research and scholarship,” describing a litany of problems with his results and methods.
He is set to resign at the end of the academic year, but from now on will no longer teach there.
Wansink denied all fraud, but 13 of his articles have already been withdrawn by journals.
In the final case, Gilbert Welch, a professor of public health at Dartmouth College, resigned last week.
The university accused him of plagiarism in an article published in The New England Journal of Medicine, the most respected American medical journal.
“The good news is that we are finally starting to see a lot of these cases become public,” said Ivan Oransky co-founder of the site Retraction Watch, a project of the Center for Scientific Integrity that keeps tabs on retractions of research articles in thousands of journals.
Oransky told AFP that what has emerged so far is only the tip of the iceberg.
The problem, he said, is that scientists, and supporters of science, have often been unwilling to raise such controversies “because they’re afraid that talking about them will decrease trust in science and that it will aid and abet anti-science forces.”
But silence only encourages bad behavior, he argued. According to Oransky, more transparency will in fact only help the public to better comprehend the scientific process.
“At the end of the day, we need to think about science as a human enterprise, we need to remember that it’s done by humans,” he said. “Let’s remember that humans make mistakes, they cut corners, sometimes worse.”
Attention has long focused on financial conflicts of interest, particularly because of the influence of the pharmaceutical industry.
But the Wansink case illustrates that other forms of conflict, including reputational, are equally important. Academic careers are largely built on how much one publishes and in which journals.
As a result, researchers compete to produce positive, new and clear results — but work that produces negative results or validates previous findings should also be rewarded, argued Brian Nosek, a professor of psychology at the University of Virginia who heads the pro-transparency Center for Open Science.
“Most of the work when we’re at the boundary of science is messy, has exceptions, has things that don’t quite fit,” he explained, while “the bad part of the incentives environment is that the reward system is all about the result.”
While moves toward more transparency have gathered momentum over the past decade, in particular among publishers of research articles, there is still a long way to go, said Nosek.
“Culture change is hard,” he argued, adding: “Universities and medical centers are the slowest actors.”